Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study.

ABSTRACT:

Aims

To determine whether sodium glucose co-transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase-4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes.

Materials and methods

We conducted a population-based cohort study using a prevalent new-user design and data from the United Kingdom Clinical Practice Research Datalink Aurum, linked to hospitalisation and vital statistics data. SGLT2i users were matched to DPP4i users on diabetes treatment intensity, duration of prior DPP4i use, calendar time, sex, age, and time-conditional propensity score. Cox models estimated the hazard ratio (HR) and corresponding 95% confidence intervals (CI) for VA with SGLT2i vs. DPP4i use. Secondary analyses str

SUBMITTER: Tang WC 

PROVIDER: S-EPMC12803592 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature